The US Food and Drug Administration has released long-awaited updated guidance on Diversity Action Plans. This guidance is stronger and very specific in places. In this panel discussion, Vistatec invites industry-leading experts Aman Khera, Joan A. Chambers, and Lya Rebelo to explore how both large and small sponsors are responding to these changes. Through real-world examples, they discuss the implications of these plans on site burden, patient experience, and how clinical operations and regulatory affairs teams are applying this US-focused guidance in global trials. Click the video to watch the recording of this essential conversation.